Bruce Kenwood, DO
Interventional Cardiology · Murray, UTNPI 1144279019
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,307 with a category attached, or 86.7%. W. L. Gore & Associates, Inc. accounts for 86.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,041 and has fallen 93.1% since, to $142 in 2025. That places this record below the midpoint for interventional cardiology clinicians in UT, where the typical reported total is $5,946.
Across 16 payments — averaging $144.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$2K
- Boston Scientific$85
- Inari Medical, Inc.$48
- Medtronic$44
- Abbott$36
- Teleflex LLC$31
- plus $63 from 3 others
What the payments were for
- Speaking & faculty fees$2,00087%
- Food & beverage$30713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 1 | $2,000 |
| Boston Scientific | 5 | $85 |
| Inari Medical, Inc. | 1 | $48 |
| Medtronic(2 entities) | 3 | $44 |
| Abbott | 1 | $36 |
| Teleflex LLC | 2 | $31 |
| Abiomed | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Stryker | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,307 in reported general payments places this provider in the 30th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $54,424 |
| Atorvastatin Calcium | 96 | $942 |
| Metoprolol Succinate | 45 | $721 |
| Flecainide Acetate | 14 | $706 |
| Carvedilol | 66 | $531 |
| ClopidogrelClopidogrel Bisulfate | 41 | $449 |
| Amlodipine Besylate | 33 | $259 |
| Lisinopril | 40 | $254 |
| Spironolactone | 31 | $201 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $171 |
| Losartan Potassium | 17 | $147 |
| Amiodarone Hcl | 12 | $112 |
| Metoprolol Tartrate | 20 | $86 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Murray
- Adam ElhaddiMurray$467
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
- Sanjeev TrehanOgden$95K
- Stavros DrakosSalt Lake City$79K
- Tareq HarbOgden$27K
- Frederick WeltSalt Lake City$26K
- Jared CrisafiSt George$24K
- Scott HackingSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.